Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 10/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.38 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.38 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712832 | 0.87 | CA2 (0.45) | PIK3CDMTORPIK3CACA2CHKA | |
| SCHEMBL20457488 | 0.79 | SLC22A12 (0.36) | CA2AURKAKDRAURKB | |
| SCHEMBL6933510 | 0.78 | NOS3 (0.56) | PIK3CDMTORPIK3CACA2CHKA | |
| SCHEMBL29899421 | 0.78 | NOS3 (0.56) | PIK3CDMTORPIK3CACA2CHKA | |
| SCHEMBL24858337 | 0.78 | NOS3 (0.56) | PIK3CDMTORPIK3CACA2CHKA | |
| SCHEMBL18590260 | 0.78 | ALOX5AP (0.42) | CA2CHKANOS3NOS2NOS1 | |
| SCHEMBL29851068 | 0.78 | NOS3 (0.56) | PIK3CDMTORPIK3CACA2CHKA | |
| SCHEMBL29498290 | 0.77 | CA2 (0.43) | PIK3CDMTORPIK3CACA2CHKA | |
| SCHEMBL24506895 | 0.77 | NOS3 (0.43) | NOS3NOS2NOS1PIK3CBALOX5AP | |
| SCHEMBL14803741 | 0.75 | NOS3 (0.58) | MTORPIK3CANOS3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266878-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA LLC (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-9018221-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140179673-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | PIK3CD 4/4885MTOR 28/4885PIK3CA 1/4885 |
| US-20140179673-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | PIK3CD 4/4885MTOR 28/4885PIK3CA 1/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PIK3CD 202/4885MTOR 206/4885PIK3CA 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.